Neurodegenerative Diseases & Medical Marijuana: Pennsylvania Qualifying Condition Guide

Neurodegenerative diseases are a broad category of progressive conditions in which nerve cells in the brain and spinal cord gradually break down and stop functioning, and, because neurons generally don’t regenerate, the damage is permanent. Pennsylvania recognizes neurodegenerative diseases as a qualifying condition for its medical marijuana program, using Alzheimer’s disease as the leading example of the category. If you or a loved one is living with a neurodegenerative disease, Compassionate Certification Centers can help you understand your options and determine whether certification may be appropriate as part of your neurological care.

It’s worth noting at the outset that several specific neurodegenerative diseases such as ALS, Huntington’s disease, Multiple Sclerosis, and Parkinson’s disease, are separately listed as their own named qualifying conditions in Pennsylvania. This page focuses on the broader neurodegenerative disease category, most commonly used for Alzheimer’s disease and related dementias, though the research summarized below touches on the category as a whole. No cannabis product is FDA-approved to treat, cure, or slow the progression of any neurodegenerative disease; the evidence to date focuses primarily on symptom management.

BOOK NOW

Pennsylvania’s medical marijuana program recognizes neurodegenerative diseases broadly, using Alzheimer’s disease as the primary example. ALS, Huntington’s disease, Multiple Sclerosis, and Parkinson’s disease are also separately listed as their own qualifying conditions in Pennsylvania. Conditions that may qualify under this broader category include:

• Neurodegenerative Disease (Alzheimer’s Disease as leading example) primary diagnosis
• Alzheimer’s Disease
• Lewy Body Dementia
• Frontotemporal Dementia
• Vascular Dementia with Progressive Neurodegenerative Features
• Friedreich’s Ataxia
• Spinal Muscular Atrophy
• Progressive Supranuclear Palsy
• Multiple System Atrophy
• Corticobasal Degeneration
• Mild Cognitive Impairment Progressing Toward Dementia

Unsure whether your diagnosis qualifies? Our certified physicians can review your documentation and help determine eligibility.

BOOK NOW

• Neurological examination assessing motor function, reflexes, and coordination
• Cognitive and neuropsychological testing
• Brain imaging (MRI, CT, or PET) to identify structural or metabolic changes
• Blood tests to rule out other treatable causes of symptoms
• Genetic testing for hereditary forms of disease, such as Huntington’s disease or Friedreich’s ataxia
• In some cases, spinal fluid analysis for biomarkers associated with Alzheimer’s disease

BOOK NOW

Because this category spans such a wide range of diseases, the strength of the evidence varies considerably depending on the specific condition and symptom being addressed. The most robust findings to date relate to agitation in Alzheimer’s-related dementia; evidence for Parkinson’s disease is more mixed, and evidence for disease-modifying or neuroprotective effects in humans remains preliminary across the board. This section presents that evidence honestly. It is informational only and does not constitute medical advice.

1. Agitation in Alzheimer’s Disease & Dementia: The Strongest Evidence in This Category

Agitation, not memory loss, is often what drives dementia patients to the emergency department or long-term care, and it is where cannabinoid research has produced some of the more compelling results. A randomized trial led by Johns Hopkins University and Tufts University School of Medicine, presented at the 2024 International Psychogeriatric Association conference, found that dronabinol (FDA-approved synthetic THC) reduced agitation in Alzheimer’s patients by an average of 30%, with a safety profile comparable to placebo and without the delirium or seizure risk associated with antipsychotics. A separate case series using CBD-rich oil reported that over 94% of dementia patients experienced at least a 30% reduction in agitation, alongside reduced caregiver distress, and a small Geneva pilot study of combined THC/CBD therapy reported improvement in both agitation and motor rigidity in patients with severe dementia. Multi-site trials at Georgetown University and the University of Maryland are now testing a combined THC/CBD oral drug (T2:C100) specifically for agitation in hospice-eligible dementia patients, aiming to offer an alternative to morphine, valium, and haloperidol. These are genuinely promising, methodologically varied findings — but most are small studies, case series, or not yet fully published in peer-reviewed form, and dronabinol’s approval remains specific to AIDS-related anorexia and chemotherapy-induced nausea, not agitation in dementia.

2. Cognitive Symptoms & Disease-Modifying Potential: Preliminary, Not Established

Separate from agitation, researchers have also explored whether cannabinoids could influence the cognitive decline or underlying disease process of Alzheimer’s itself. A 2025 phase 2, randomized, double-blind, placebo-controlled trial tested a low-dose THC-CBD extract over 26 weeks in patients with Alzheimer’s-associated dementia, evaluating safety and effects on cognitive and behavioral measures. This kind of trial reflects genuine, ongoing scientific interest in whether cannabinoids might meaningfully affect cognition or disease course — but this remains an active, unsettled research question. No cannabinoid product has been shown in high-quality human trials to slow, halt, or reverse the progression of Alzheimer’s disease or any other neurodegenerative condition, and none is FDA-approved for this purpose.

3. Parkinson’s Disease: Encouraging Patient-Reported Relief, but Mixed Trial Results

Patient surveys and observational studies in Parkinson’s disease consistently report improvement in tremor, rigidity, bradykinesia, dyskinesia, sleep, and pain among cannabis users. However, a 2021 systematic review and meta-analysis of 15 studies, including six randomized controlled trials, concluded that while observational data establishes patient interest and subjective symptom relief, there is insufficient high-quality RCT evidence to support integrating cannabis into standard Parkinson’s treatment for motor symptoms. This gap between patient-reported experience and controlled trial evidence was reinforced by a 2024 randomized trial that found a CBD/THC combination produced no significant motor benefit over placebo, and, notably, was associated with a small negative effect on cognition, sleep, and daily activities compared to placebo — a reminder that patient-reported benefit and rigorous trial evidence don’t always align, and that cannabinoids are not risk-free even when patients feel they’re helping.

4. The Endocannabinoid System & Neuroprotection: Biological Rationale, Preclinical Stage

The endocannabinoid system, through CB1 and CB2 receptors, is involved in regulating inflammation, oxidative stress, and neuronal signaling — all processes implicated in neurodegenerative disease. Preclinical research has explored whether cannabinoids might reduce amyloid plaque formation in Alzheimer’s models or protect dopamine-producing neurons in Parkinson’s models. This research provides biological plausibility for further study, but it has not been established in human clinical trials, and no cannabinoid product currently offers proven neuroprotective or disease-modifying benefit in people.

5. Safety Considerations Specific to Older & Cognitively Impaired Patients

Neurodegenerative disease patients are often older, may already have gait instability or fall risk, and are frequently on multiple medications — all factors that raise the stakes around cannabis-related sedation, dizziness, and confusion. Because THC can independently cause transient impairment in memory and attention, its use in patients who are already experiencing cognitive decline requires particular care, and as the 2024 Parkinson’s trial illustrated, cannabinoids can sometimes worsen rather than improve cognitive or functional measures. Patients and caregivers should discuss dosing, cannabinoid ratios, fall risk, and interactions with existing medications carefully with a certified physician, and cannabis should always be considered alongside — not in place of — standard neurological care.

BOOK NOW

Pennsylvania recognizes neurodegenerative diseases as a qualifying condition. The certification process with CCC is straightforward:

Step 1: Register over the phone or online next-day appointments are often available.
Step 2: Meet with a certified medical marijuana physician who will review your IBD diagnosis, current treatment plan, and symptom profile to determine whether certification is appropriate.
Step 3: Receive your medical marijuana card and begin purchasing from licensed dispensaries.